The voluntary scheme, which has been welcomed by Farming Minister George Eustice and Welsh Government Cabinet Secretary for Environment and Rural Affairs Lesley Griffiths, improves a herd’s ‘score’ every year it is free from a bTB breakdown, awarding a status of 0-10.
This new bTB scheme will require the herd vet and cattle owner to work together on following a number of biosecurity measures already successfully implemented in five other cattle disease control programmes.
As well as reducing risk of infection, the country-wide programme could present informed purchasing opportunities. In particular, it could benefit farmers selling cattle from regions with a high risk of the disease or who wish to minimise exposure from bought-in animals. It could also give recognition for a farmer’s efforts to complement Government and industry strategies to control infection.
Farming Minister George Eustice (pictured left above, with BCVA President Andrew Cobner) said: "Dealing with Bovine TB is costing us £100 million a year and causing devastation and distress for farmers and rural communities across the country. 33,000 cattle were slaughtered because of the disease last year alone and many farms are subject to movement restrictions which can affect their trade.
"But we know some 40% of herds in the high-risk area in England have never had a breakdown, and the CHeCS scheme will help them to communicate this so they can carry out risk-based trading to support their businesses.
"The scheme will also recognise those practicing good biosecurity, which is a core part of our long-term plan to tackle bovine TB."
The scheme complements the Government’s 25-year plan to eradicate Bovine TB in England, and will provide another tool for farmers who want to show they are following best practice. It follows the launch of the TB Hub (www.tbhub.co.uk), which offers practical advice and guidance as well as background into the disease.
The Cabinet Secretary, Mrs Griffiths, said: "The Welsh Government has been supportive of this initiative from the start. By focusing on individual herds, the scheme complements our proposed regional approach, for example those herds in the high TB areas which have not recently had TB will be able to demonstrate they are a lower risk.
"This industry-led initiative aimed at reducing TB is to be welcomed and fits in with our principles of working in partnership and promoting the benefits of disease prevention. I urge Welsh farmers to engage with the scheme and reduce the risk of disease being introduced into their herd."
Across Great Britain, CHeCS has over 14,000 member herds, representing around 14% of cattle holdings in some form of monitoring, control and eradication of disease.
Keith Cutler, CHeCS board member and partner in the Endell Veterinary Group, said: "CHeCS so far has focused on control of non-statutory diseases – Johne’s Disease, IBR, BVD, Leptospirosis and Neospora. Participating health schemes have been monitoring the health status of participating herds for some years.
"With this programme, we will be working with Government to receive official TB test data with the agreement of the farmer. It’s an exciting development for CHeCS, but there is a natural fit because of the expertise CHeCS-accredited health schemes already have with monitoring biosecurity measures on their members’ farms."
Andrew Cobner, president of the British Cattle Veterinary Association, who has been technical lead on the project since the start, said: "All too often we are confronted with the view that there is little or nothing that we can do to control TB. We wouldn’t accept this attitude with any other infectious disease so it’s time farmers and vets fought back. We have a government that is willing to embrace all of the measures necessary and we have a 25 year plan in place. Part of this will involve increasing biosecurity and risk-based trading, and CHeCS is leading the way."
The CHeCS bTb Herd Accreditation scores run from 0 (following all CHeCS measures but had a herd breakdown within the past 12 months), to 1 (following CHeCS measures and one year since the last herd breakdown) all the way though to 10 (following CHeCS measures and 10 years or more since the last herd breakdown).
Veterinary surgeons who think their clients might want to know more can point them in the direction of: www.checs.co.uk to read the technical standard, programme handbook and Q&A. If it sounds advantageous to their farm, they should discuss joining with you, then contact one of the participating CHeCS-accredited health schemes listed on the website. The application form includes a privacy agreement to allow the Animal and Plant Health Agency (APHA) to send test data automatically to the health scheme, and a declaration from the herd vet. After the form is sent back, a starting score will be awarded.
More information on bTB is also available at www.tbhub.co.uk.
The company has published data from its 2021 Assure Ewe subsidised testing scheme, which found that 48% of farms that submitted samples after last year’s lambing season tested positive for EAE1 caused by Chlamydia abortus.
This, Ceva says, mirrors the results from the 2020 testing initiative, demonstrating that EAE remains a significant issue on UK farms.
Katherine Timms BVetMed (Hons) MRCVS, ruminant veterinary advisor at Ceva Animal Health said: “EAE is a significant problem on UK farms, and it can be exceptionally expensive and frustrating to deal with, as infected sheep aborting and shedding have the potential to cause an abortion storm the following year.
“Any abortion outbreak should therefore be identified and managed as quickly and effectively as possible to help prevent the rest of the ewes in the flock from becoming infected.
"Vaccination and strict biosecurity provide the best protection against EAE and farmers can vaccinate their ewes from five months of age until four weeks prior to tupping, as long as the ewe is not in lamb.”
For further information, contact your local Ceva Animal Health account manager or visit www.enzooticabortion.co.uk.
Reference
The webinar, titled: ‘When the coughing won’t stop…. what to do when standard BRD treatment protocols aren’t getting to the bottom of it’, aims help vets manage complex outbreaks that happen despite best practice management and treatment protocols.
The full programme includes:
The event is being held live so you can submit questions to the speakers, but the session will be recorded, so it can be watched again later.
Attendees will receive a certificate for one hour of CPD and the link to the recorded webinar.
To register, email the event team by 27 November 2020 at brdwebinar-group@ceva.com. In the email, please give your name and the email address to which you would like the registration link sent.
The Boehringer Academy (www.boehringer-academy.co.uk) contains hundreds of hours of CPD material on equine, companion and production animals. It comprises a mixture of webinars, podcasts, short videos and downloadable documents, which can be viewed at any time. The site keeps a CPD log for each user and provides downloadable certificates.
Boehringer’s Small Animal Marketing Team Leader, Jemima Mead said: "We already have just over 15,000 vets and nurses in the UK and Ireland currently registered with the Academy.
"New and existing members are eligible to receive the Boehringer Academy colouring book. They simply have to visit www.boehringer-academy.co.uk and complete their profile. In addition, everyone completing their profile will be entered into a draw to win an iPad Pro and Apple Pencil."
The workshop will be hosted by Renzo Di Florio (pictured right), veterinary advisor at Ceva Animal Health.
The session will look at the impact of Q Fever in the UK, outlining how it affects cattle health and reproductive performance and productivity.
It'll also cover identification of the disease and diagnosis, and prevention through vaccination and treatment.
For further information and to book tickets for TotalDairy, visit www.totaldairy.com (Ceva can offer a 10% discount on the purchase of tickets to the event using the code CEVA10).
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
CEVA Animal Health has launched the anti-inflammatory Meloxidyl for cattle and pigs.
Meloxidyl is meloxicam-based solution for the management of respiratory disease, mastitis and diarrhoea in cattle and non-infectious locomotor disorders and puerperal septicaemia and toxaemia in pigs. It is given via a single injection, when used in combination with suitable anti-infectives.
According to the company, Meloxidyl's one shot protocol means it is quick and economical to use; it allows control of inflammation and endotoxins and reduces somatic cell count, recovery time and risk of culling after clinical mastitis; it reduces the economical impact of respiratory signs in comparison with flunixin-based products and reduces the major clinical signs caused by toxins in cases of neonatal diarrhoea.
Meloxidyl can be used in combination with the company's range of anti-infectives, which includes Marbokem, Cevaxel and Florkem.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
References
The recategorisation means that pharmacists and Suitably Qualified Persons (SQPs) will be able to prescribe Zolvix.
The VMD says that making the anthelmintic more widely available will increase its usage as part of strategic worm control programmes on farms, which could in turn result in long term health benefits for sheep, for example by reducing the development and spread of anthelmintic resistance, thereby prolonging the effective use of anthelmintics.
The VMD adds that SQPs will now have additional training to ensure they are sufficiently familiar with Zolvix and how to prescribe it effectively and responsibly so that it is used appropriately. A new compulsory training module will be implemented by The Animal Medicines Training Regulatory Authority (AMTRA) to augment the skills of all AMTRA-registered SQPs permitted to prescribe farm animal products. New SQPs will be required to undertake a revised and extended module before gaining their farm animal registration with AMTRA.
Pharmacists and SQPs will be able to prescribe Zolvix from 1st July 2017.
UPDATE 16th March:
BVA President Gudrun Ravetz has issued a statement expressing concern over the recategorisation of Zolvix:
"We know that resistance to anthelmintics is increasing in grazing animals and needs to be addressed if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites. The reclassification of Zolvix from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is a serious threat to animal welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in group 4 as a result.
"BVA believes that prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis, in order to protect animal welfare and safeguard the efficacy of these products for the future."
Further information on BVA's policy on anthelmintics can be found on BVA’s website: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics.
Fort Dodge Animal Health has announced that its Zulvac 8 Ovis® Bluetongue sheep vaccine is now licensed and available in the UK. The company believes that the product will provide significant benefits to sheep farmers.
Zulvac 8 Ovis® is an inactivated adjuvanted vaccine for the active immunisation of sheep by subcutaneous injection against Bluetongue Serotype 8. It also provides a reduction in viraemia. Administration is a two x 2 ml dose primary course in year one but only a single shot booster in the second year.
The use of Zulvac 8 Ovis as a booster for animals previously vaccinated with a primary course from other manufacturers is in line with Defra (2009) guidance: 'No problems are anticipated with re-vaccinating animals which have already received a primary course of vaccination with a different vaccine 1'.
The first dose can be administered from one month of age and Zulvac 8 Ovis® is proven for use in pregnant sheep. The onset of immunity is provided 25 days after the second dose.
Fort Dodge says Zulvac provides cost savings to farmers through its pricing strategy. While the price for the two dose primary course is competitive with alternative vaccines, for animals which were vaccinated last year and require only a single shot booster, the cost will be half that of competitive offerings, providing a significant incentive to farmers to vaccinate.
The vaccine is supported by a specific Zulvac Ovis fixed 2ml dose applicator with Sterimatic needle protector and cleaning system which aids administration and hygiene and is sold separately.
David Bartram MRCVS, Veterinary Technical Manager at Fort Dodge, said: "Sheep farmers have been waiting for a Bluetongue vaccine which offers a cost effective solution to vaccination - particularly for animals which received their primary course last year and are simply in need of a booster. We expect the fact that it's licensed for use in pregnant sheep to also prove attractive.
"Zulvac 8 Ovis® is the latest addition to Fort Dodge's Zulvac range for both cows and sheep. It is already used in Europe and has helped protect millions of animals."
The BVA has challenged the Food Standards Agency (FSA) to take further investigative action to enable Defra to consider prosecutions against the Essex abattoir where appalling animal welfare abuses were highlighted in footage obtained by Animal Aid.
The footage shows pigs being abused and manhandled in breach of animal welfare legislation.
BVA President Harvey Locke said: "There must be confidence in the systems that regulate and license slaughter and the people responsible for carrying it out. I have written to the Chief Executive of the FSA outlining our concerns at the lack of any action towards prosecution.
"The method by which the issue was highlighted should not, in our opinion, preclude further investigation by the FSA and Defra into these incidents with a view to lawfully obtaining evidence to either support or refute the accusations arising from the Animal Aid footage."
Mr Locke added: "The UK food industry prides itself on high welfare standards. Animal cruelty is not acceptable and action must be taken. These are serious welfare issues and investigations into this sort of blatant abuse and appalling treatment of animals must be pursued vigorously."
In his letter to the FSA Mr Locke reiterated the BVA's views on the specific issue of CCTV in abattoirs at the stunning/slaughter point, stressing that Food Business Operators (FBOs) must have effective procedures in place either to constantly monitor stunning and slaughter operations, or to enable the FBO or their Animal Welfare Officer to inconspicuously observe stunning and slaughter operations at any time: such arrangements may include an aperture or window into the stunning area or the use of CCTV by the FBO for welfare monitoring and management purposes.
Join the discussion here.
The study, which was carried out by researchers from the School of Veterinary Medicine and Sciences at the University of Nottingham, is one of the first to look at colostrum hygiene in Great Britain. The researchers analysed data from 328 colostrum samples from 56 British dairy farms.
Samples collected from collection and feeding equipment had higher levels of bacteria than those collected directly from the cows’ teat, suggesting that whilst colostrum from the cow is relatively low in bacterial levels, improperly cleaned equipment can be a major source of bacterial contamination. Over one third of samples collected from collection or feeding equipment were over the threshold for high bacterial levels and represented a significant risk to the health of calves.
Dr Robert Hyde (pictured right), one of the researchers on the study, said: “By analysing colostrum collection protocols on the farms, we were able to identify a small number of management practices likely to have a substantial impact on colostrum hygiene for the majority of farms.
"For example, the use of scalding hot water to clean collection and feeding equipment could reduce bacteria levels by over 90% compared with using cold water only. Less than half of farms used scalding hot water to clean colostrum collection and feeding equipment, suggesting there are a large number of farms that could make this simple change.”
The main recommendations from the research are that colostrum hygiene protocols should include the cleaning of colostrum collection and feeding equipment after every use with hot water as opposed to cold water, and hypochlorite or peracetic acid as opposed to water or parlour wash.
Cows' teats should be prepared with a pre-milking teat disinfectant and wiped with a clean, dry paper towel prior to colostrum collection, and colostrum should be pasteurised where possible.
The AHDB guide to colostrum hygiene can be found here: https://www.youtube.com/watch?v=FziQX0B9yb4
Robert added: “This study provides a first look at bacteria levels in Great Britain, and the results suggest there are a few simple changes to collection and cleaning protocols that could have a significant impact on colostrum hygiene levels on British dairy farms. By making these simple changes there is likely to be significant improvement in colostrum hygiene, which is essential in minimising the risk of disease and ensuring the optimum health and welfare of calves on dairy farms.”
The full study is open access and can be found here: https://www.frontiersin.org/articles/10.3389/fvets.2020.601227/full
The University of Nottingham herd health toolkit contains a “Colostrum bacteriology” section, where vets and farmers can use the results from this study to see what management changes might have the largest impact on colostrum hygiene, can be found here: https://herdhealth.shinyapps.io/toolkit/
A 2021 German study reported the incidence of diarrhoea to be 18.5% and the most common disease observed in almost 14,000 neonatal calves examined on 731 dairy herds1.
Fencovis is indicated for the active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.
Boehringer says that in calves fed with colostrum and milk from vaccinated cows, these antibodies have been demonstrated to prevent diarrhoea caused by rotavirus and E. coli F5 (K99) adhesin and reduce the incidence and severity of diarrhoea caused by coronavirus.
Viral shedding in calves infected by rotavirus and coronavirus was also reduced by Fencovis.
Findlay MacBean, Business Head Livestock at Boehringer Ingelheim UK & Ireland, said: “We are delighted to announce the launch of Fencovis, the first vaccine that is licensed to prevent calf scour caused by Rotavirus and E. coli F5 (K99), and also reduce the incidence and severity of scour associated with coronavirus infection. ”
Fencovis is a suspension for injection which uses a non-oil adjuvant. It comes in a variety of presentations including a single dose pack.
Tri-Solfen contains lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia, adrenalin to reduce blood loss and cetrimide to lower the risk of infection.
Dechra says the gel is effective in 30 seconds, making it a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals.
According to the company, more than 100 million animals have been treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
www.dechra.co.uk
Ceva says CLAS vials are proven to be easy to use, practical and eco-friendly and are preferred by 99% of farmers on farm1. They have 33% less impact on the environment from cradle to grave than glass2 and are robust and shock resistant3 for fewer breakages and losses. They are made from a lightweight material to make the vials easier to be transported and handled4 and have an ergonomic ‘grip groove’ for easier handing5.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "Ceva’s CLAS vials are hugely popular with both vets and farmers due to their practicality, ease of use and environmental credentials.
“We are therefore delighted that Ketofen has joined the extensive range of livestock injectables available in CLAS.”
For further information contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
A new injectable antibiotic with nil-milk-withhold licensed to treat foul-in-the-foot in a single shot has been launched by Pfizer Animal Health.
Naxcel Cattle's active ingredient is ceftiofur in a patented sustained-release formulation. According to the company, one injection provides a full course of antibiotic therapy, giving seven days of therapeutic blood levels against the majority of inter-digital necrobacillosis ('foul-in-the-foot') pathogens.
Pfizer vet Dave Gilbert says the expectation is that Naxcel Cattle will make on-farm therapy easier and help improve treatment compliance and thereby first treatment success rates, compared to treatments which require repeat injections. "Having the full course in a single injection simplifies treatment protocols and eliminates a number of reasons for non-completion of treatment, such as forgetting a second or third dose, or not giving them because of apparent symptomatic recovery from the condition."
The site of injection for Naxcel Cattle is the subcutaneous area at the base of the ear (see Figures 1 & 2). Injection instructions are supplied in the product pack. Dave Gilbert suggests that provided cattle are adequately restrained during administration the injection technique is simple and straightforward. The dose rate is 1ml/30kg body weight and up to 30ml can safely be given into each site.
Figure 1. Subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).Figure 2. Injection location for the subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).
The RCVS has announced that registrations for the new RCVS Register of Veterinary Practice Premises will be accepted from 1 November 2008, allowing all those who wish to supply medicines from veterinary practice premises from 1 April 2009 onwards a full five months to comply with the latest medicines legislation.
In order to fulfil its obligations under European law to maintain and improve traceability of, and accountability for, veterinary medicines, the UK Government decided that any veterinary surgeon may only supply veterinary medicinal products (VMPs) from premises registered with the Secretary of State, with effect from 1 April 2009.
The Veterinary Medicines Directorate (VMD) is responsible for the inspection and registration of practices under the Veterinary Medicines Regulations. Steve Dean, VMD's Chief Executive, says the new veterinary practice premises register will complete the UK information base by bringing veterinary practices in line with other suppliers of veterinary medicines who already have to operate from registered premises.
The Register will enable the supply of veterinary medicines by veterinary surgeons, including controlled drugs, to be subjected to inspection and verification. As a result, DEFRA Ministers and the European Commission can be re-assured that veterinary medicines are being supplied in the UK in accordance with EC legislation.
In discussion with the VMD, it was agreed that the most appropriate body to maintain this register would be the RCVS, not least because the College already manages the RCVS Practice Standards Scheme and publishes the (voluntary) Directory of Veterinary Practices, so has the necessary systems already in place. The register will be published on RCVSonline and updated quarterly.
Whilst there will now be a statutory fee levied for each practice premises registered on the new Register, the College's existing database framework has kept this to a relatively low £40 compared to what other bodies might have had to charge after starting from scratch.
Practices could appear in the Directory for free because the cost of producing it was partially covered by subsequent data sales. However, the new Register will need to be self-funding, as the data it contains will be freely available online.
Not all practices will have to pay the statutory fee. RCVS President Jill Nute said: "For those practice premises already accredited under the RCVS Practice Standards Scheme (PSS), the fee will be taken from their existing PSS annual fee.
"What's more, accredited practices will not face additional four-yearly inspections by VMD inspectors (unless there is an investigation for enforcement purposes) as their PSS inspections already ensure that they keep up to date with current medicines legislation."
Practice premises that have applied to join the Scheme, but have not yet been accredited, will not face additional VMD inspections either, but will still need to pay the statutory fee.
To help practices understand the new requirements and what they need to do before next April, the RCVS has produced a range of guidance, including a series of Frequently Asked Questions (www.rcvs.org.uk).
"In particular, we hope this guidance will help to explain which premises are likely to be considered ‘veterinary practice premises' and the difference between those premises and places where medicines might simply be stored or kept," said Mrs Nute.
"It is important to realise that there is a legal requirement to register veterinary practice premises for the supply of medicines, and a professional obligation, set out in the Guide to Professional Conduct, to keep a record of where all medicines are stored or kept. This record should avoid the need for additional registration of car boots, farms and homes."
Over the coming weeks, application forms will be posted to all practices currently listed in the Directory and accredited under the PSS, containing all the practice information currently held. These forms must be checked, signed and returned, even if no fee is due. Separate application forms will be available for any non-accredited practice premises not published in the Directory, and a letter will be sent to all RCVS members to ensure the whole profession is aware of the new requirements.
CEVA Animal Health has extended its range of injectable anti-infectives with Florkem, a Florfenicol-based antimicrobial for the treatment of respiratory tract infections in cattle and pigs.
According to the company, Florfenicol shows a strong in vitro bactericidal activity against the most common respiratory tract pathogenic bacteria and can be used as a time or dose-dependent bactericidal depending on the target. It also offers very good diffusion in most tissues for an efficient response.
CEVA says Florkem® is very convenient to use: a specifically developed formulation provides for better syringeability, in both warm and cool temperatures, making administration quicker and easier. It is presented in an ergonomic CLAS vial, which is shock resistant, light and easy to handle in the field. This means fewer breakages, which can reduce costs while maintaining efficacy.
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
Woodley Equipment Company has announced that Veterinary Parasep Faecal Filters are now available exclusively from the company.
According to the Woodley, the filters have been developed in conjunction with an independent leading veterinary Institution and offer an improved method of determining Worm Egg Counts (WEC) on cattle, sheep and horses. Flotation methods for WEC can require several Specific Gravity solutions to cover different parasites. The two common flotation methods, ‘Modified McMaster' and ‘Improved Modified McMaster', both use Saturated NaCL and are both catered for with Veterinary Parasep.
Woodley says the key advantages of the new filters are:
For a more information about The Veterinary Parasep please email sales@woodleyequipment.com or call the customer service team on +44 (0) 1204 669033 ~ Option 1.
Alternatively, visit http://www.woodleyequipment.com/.
New legislation will be introduced in the New Year making slaughterhouse CCTV a legal requirement in all areas where live animals are present, with unrestricted access to at least 90 days of footage for Official Veterinarians. The new law will come into force in the spring, with slaughterhouses allowed an adjustment period of up to six months.
The new legislation followed a public consultation which was overwhelmingly in favour of compulsory CCTV. Defra says that out of almost 4,000 respondents, more than 99% were supportive of the plans.
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and want to cement our status as a global leader by continuing to raise the bar.
"The reaction to this consultation highlights the strength of feeling among the public that all animals should be treated with the utmost respect at all stages of life and be subject to the highest possible welfare standards.
"These strong measures also provide a further demonstration to consumers around the world that as we leave the EU we continue to produce our food to the very highest standards."
BVA Senior Vice President Gudrun Ravetz said: "The mandatory installation of CCTV is a vital tool to ensure high standards of animal health, welfare and food safety in all slaughterhouses.
Official Veterinarians carry out an essential role in slaughterhouses by independently assessing and reporting breaches of animal welfare, and unrestricted access to CCTV footage will allow them to carry out this role even more effectively.
We have been campaigning for these measures for a number of years and it is reassuring to see such a high level of support for their implementation from industry and the public."
Heather Hancock, Chairman of the Food Standards Agency, said: "The Secretary of State’s decision to require CCTV in all slaughterhouses is a welcome step towards ensuring that animal welfare and hygiene standards are met across the meat industry.
"Last year, the FSA Board concluded that, without mandatory CCTV in slaughterhouses, we would see minimal further progress in businesses improving animal welfare or complying with official controls to protect public health.
"We look forward to working with the industry as CCTV plans are implemented, and to seeing public confidence rise as a result."
The government will now further discuss the details of bringing in the proposals and present draft legislation to Parliament as soon as Parliamentary time allows.
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
Agrimin has announced the launch of a new range of boluses for sheep and cattle that use 'eroding technology' to deliver a sustained supply of three trace elements for up to 180 days:
According to Agrimin, each bolus is designed to provide the full daily requirement of cobalt and selenium and the largest available daily supply of iodine to both cattle and sheep. The boluses do not contain any copper, an element known to cause issues in certain parts of the country, in closely managed dairy cows or in continental sheep breeds.
Each bolus is made up of two parts, held together by a soluble wrapper. After administration, the wrapper dissolves and the two halves remain in the reticulum where they erode and dissolve. This process delivers a continuous and regular supply of nutrients to the animal.
Agrimin's Dr Jamie Bennison said that the new range has been extensively trialled in New Zealand and at Glasgow Veterinary School: "Trials have confirmed a sustained release profile which ensures that iodine, selenium and cobalt levels are maintained throughout the active life of the bolus. In farm trials this has translated into higher levels of the elements in blood samples and improved animal productivity."
Treatment is one bolus per animal (48g for sheep; 160g for cattle) administered with an Agrimin bolus gun. One bolus is sufficient to meet the animal's full daily requirement for 180 days.
For more information about the 24•7 Iodine•Selenium•Cobalt range of cattle and sheep boluses, please visit http://www.agrimin.com/ or call 01652 688046.
Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.
Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml. It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections.
In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.
Ketodale is available in 50ml and 100ml vials.
To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only.
To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com
The Soil Association is calling on the Government to issue guidelines that will limit the veterinary use of the most modern penicillin-type antibiotics, to prevent the spread of a serious new superbug.Recently released minutes of a Government committee reveal that Ministers have been briefed about the emergence on a British dairy farm of a mutant strain of antibiotic-resistant E. coli which causes life-threatening cases of food poisoning, including hemorrhagic colitis and haemolytic uraemic syndrome.
The bug, known as E. coli O26 is a vera-toxin producing E. coli (VTEC), similar to the infamous E. coli O157. According to the Soil Association, what makes the discovery of this variant so significant is that this is the first time in the UK, and only the third time in the world, that VTEC E. coli has been found with an enhanced type of antibiotic resistance known as extended-spectrum beta-lactamase (ESBL), which makes it resistant to almost all antibiotics. ESBL resistance has previously been found on 57 UK farms, but until now only in strains of E. coli that cause urinary tract infections and blood poisoning.Although antibiotics are not recommended for the treatment of VTEC E. coli, scientists warn that the emergence of resistance is undesirable because these resistant bacteria are encouraged every time certain antibiotics are used, resulting in increased spread and greater risk of contaminated food products. On non-organic dairy farms, cows are routinely given antibiotics at the end of their lactation to prevent mastitis. In addition, milk from cows given antibiotics for treatment, or prevention, is often fed to calves when it contains residues and cannot be sold. However, because ESBL E. coliO26 is resistant to all the antibiotics used in ‘dry cow therapy' and many of those used for treatment, the high use of antibiotics on dairy farms will promote the rapid spread of these dangerous bacteria.Soil Association Policy Adviser, Richard Young said: "This is one of the most worrying developments in the continuing rise of ESBL E. coli. Today is the first European Antibiotics Awareness Day, but there is a distinct lack of awareness that the continuing high use of antibiotics in farming is contributing to the increase in antibiotic-resistant infections in humans."The Government often calls on doctors to prescribe antibiotics less often. But similar advice needs to be given to veterinary surgeons and farmers. Half of all antibiotics are given to animals, and there is mounting evidence that antibiotic-resistant bacteria in farm animals pass to humans. If we want antibiotics to save lives in the future as they have done in the past then the Government must provide specific recommendations based on scientific advice, and vets need to pull together with doctors to limit the use of problematic drugs."